Gibel announced that it has obtained a patent for compounds in the development of a new antineoplastic drug (JJH201601).
The chairman of the company is Geng Zhongyi. Mr. Geng Zhongyi: born in 1963, Chinese nationality, no permanent residence abroad, bachelor's degree, senior economist, licensed pharmacist, Mr. Geng Zhongyi has worked in Yancheng Pharmaceutical Company, Zhenjiang Pharmaceutical Industry Research Institute, Zhenjiang No. 3 Pharmaceutical Factory, Zhenjiang Yangtze River Sanitary products Factory, Zhenjiang second Pharmaceutical Factory, Zhenjiang Zhongtian Pharmaceutical Co., Ltd., served as technical director, factory director, general manager, chairman and other positions From November 2001 to September 2014, he served as chairman of Jiangsu Jibel Pharmaceutical Co., Ltd., and served as chairman and general manager of the company since September 2014. Mr. Geng Zhongyi personally participated in the research and development of many new drug projects of the company, applied for a number of invention patents related to nitrenolol tablets, antidepressants and other related inventions, and won the first prize of science and technology in Shanghai. it has been awarded as the advanced individual of scientific and technological cooperation in Zhenjiang, the scientific and technological pacesetter of Zhenjiang, the excellent scientific and technological worker in Zhenjiang, the training object of the first batch of "Science and Technology Entrepreneur training Project" in Jiangsu Province, Jiangsu Science and Technology Entrepreneur and other titles. He is also the executive director of China Pharmaceutical quality Management Association, the director of Jiangsu Medical quality Management Association, and the honorary chairman of Zhenjiang Pharmaceutical Association.
This article is compiled by the Securities Star data Center according to the public data and does not constitute investment opinions or suggestions. If you have any questions, please contact us.